Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPM1B | O75688 | 1/20 | 0.44 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.44 |
| ▸ | PPP1CC | P36873 | 1/20 | 0.44 |
| ▸ | TP53 | P04637 | 1/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Ethylene Glycol SCHEMBL9894391 | 1.00 | PPM1B (0.44) | PPM1BPTPN1PPP1CCTP53CYP3A4 | |
| Ethylene Glycol SCHEMBL1296288 | 1.00 | PPM1B (0.44) | PPM1BPTPN1PPP1CCTP53CYP3A4 | |
| SCHEMBL30142964 | 0.94 | PPM1B (0.47) | PPM1BPTPN1PPP1CCTP53CYP3A4 | |
| SCHEMBL30553087 | 0.94 | PPM1B (0.47) | PPM1BPTPN1PPP1CCTP53CYP3A4 | |
| SCHEMBL12987462 | 0.94 | PPM1B (0.47) | PPM1BPTPN1PPP1CCTP53CYP3A4 | |
| SCHEMBL1296411 | 0.94 | PPM1B (0.47) | PPM1BPTPN1PPP1CCTP53CYP3A4 | |
| SCHEMBL13011624 | 0.94 | PPM1B (0.47) | PPM1BPTPN1PPP1CCTP53CYP3A4 | |
| SCHEMBL595642 | 0.91 | PPM1B (0.47) | PPM1BPTPN1PPP1CCTP53CYP3A4 | |
| SCHEMBL595640 | 0.91 | PPM1B (0.47) | PPM1BPTPN1PPP1CCTP53CYP3A4 | |
| SCHEMBL595641 | 0.91 | PPM1B (0.47) | PPM1BPTPN1PPP1CCTP53CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9771466-B2 | Glycol ether-based cyclohexanoate ester plasticizers and blends therefrom | EXXONMOBIL CHEMICAL PATENTS INC. (US) | 2017-09-26 | — | — | US | claimed |
| US-20150112008-A1 | Glycol Ether-Based Cyclohexanoate Ester Plasticizers and Blends Therefrom | EXXONMOBIL CHEMICAL PATENTS INC. | 2015-04-23 | — | — | US | claimed |
| US-9771466-B2 | Glycol ether-based cyclohexanoate ester plasticizers and blends therefrom | EXXONMOBIL CHEMICAL PATENTS INC. (US) | 2017-09-26 | — | — | US | disclosed |
| US-9228147-B2 | Glycol ether-based cyclohexanoate esters, their synthesis and methods of use | EXXONMOBIL RESEARCH AND ENGINEERING COMPANY (US) | 2016-01-05 | — | — | US | disclosed |
| US-20150112008-A1 | Glycol Ether-Based Cyclohexanoate Ester Plasticizers and Blends Therefrom | EXXONMOBIL CHEMICAL PATENTS INC. | 2015-04-23 | — | — | US | disclosed |
| WO-2012082826-A1 | GLYCOL ETHER-BASED CYCLOHEXANOATE ESTERS, THEIR SYNTHESIS AND METHODS OF USE | EXXONMOBIL RESEARCH AND ENGINEERING COMPANY (US) | 2012-06-21 | — | — | WO | disclosed |
| US-20120149620-A1 | GLYCOL ETHER-BASED CYCLOHEXANOATE ESTERS, THEIR SYNTHESIS AND METHODS OF USE | EXXONMOBIL RESEARCH AND ENGINEERING COMPANY (US) | 2012-06-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120149620-A1 | GLYCOL ETHER-BASED CYCLOHEXANOATE ESTERS, THEIR SYNTHESIS AND METHODS OF USE | GNE, UGT8, GK | PPM1B 4666/4885PTPN1 4462/4885PPP1CC 1560/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.